» Articles » PMID: 26500551

HDL Particle Number and Size As Predictors of Cardiovascular Disease

Overview
Journal Front Pharmacol
Date 2015 Oct 27
PMID 26500551
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies indicate that reduced concentrations of circulating high-density lipoprotein (HDL) particles can be superior to HDL-cholesterol (HDL-C) levels as a predictor of cardiovascular disease. Measurements of HDL particle numbers, therefore, bear a potential for the improved assessment of cardiovascular risk. Furthermore, such measurement can be relevant for the evaluation of novel therapeutic approaches targeting HDL. Modern in-depth analyses of HDL particle profile may further improve evaluation of cardiovascular risk. Although clinical relevance of circulating concentrations of HDL subpopulations to cardiovascular disease remains controversial, the negative relationship between the number of large HDL particles and cardiovascular disease suggests that assessment of HDL particle profile can be clinically useful. Reduced mean HDL size is equally associated with cardiovascular disease in large-scale clinical studies. Since HDL-C is primarily carried in the circulation by large, lipid-rich HDL particles, the inverse relationship between HDL size and cardiovascular risk can be secondary to those established for plasma levels of HDL particles, HDL-C, and large HDL. The epidemiological data thereby suggest that HDL particle number may represent a more relevant therapeutic target as compared to HDL-C.

Citing Articles

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?.

Lan N, Watts G Curr Atheroscler Rep. 2025; 27(1):35.

PMID: 40009132 PMC: 11865134. DOI: 10.1007/s11883-025-01281-3.


Analysis of TEM micrographs with deep learning reveals APOE genotype-specific associations between HDL particle diameter and Alzheimer's dementia.

Zheng J, Hong B, Agus J, Tang X, Guo F, Lebrilla C Cell Rep Methods. 2025; 5(1):100962.

PMID: 39874947 PMC: 11840948. DOI: 10.1016/j.crmeth.2024.100962.


Childhood body size, adulthood adiposity, underlying mechanisms, and risk of incident hypertension: a prospective cohort study of 180,527 participants.

Ma S, Liu X, Lin R, Yao Y, Zhao M, Yu Y BMC Med. 2025; 23(1):47.

PMID: 39871294 PMC: 11773732. DOI: 10.1186/s12916-025-03884-8.


Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.

Andersen C, Fernandez M Nutrients. 2025; 17(1.

PMID: 39796476 PMC: 11722654. DOI: 10.3390/nu17010042.


ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III.

Rehues P, Girona J, Guardiola M, Ozcariz E, Amigo N, Rosales R Cardiovasc Diabetol. 2024; 23(1):433.

PMID: 39633383 PMC: 11619673. DOI: 10.1186/s12933-024-02531-5.


References
1.
Gordon S, Deng J, Lu L, Davidson W . Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res. 2010; 9(10):5239-49. PMC: 3100175. DOI: 10.1021/pr100520x. View

2.
Rosenson R, Otvos J, Freedman D . Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002; 90(2):89-94. DOI: 10.1016/s0002-9149(02)02427-x. View

3.
Camont L, Lhomme M, Rached F, Le Goff W, Negre-Salvayre A, Salvayre R . Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013; 33(12):2715-23. DOI: 10.1161/ATVBAHA.113.301468. View

4.
Jeyarajah E, Cromwell W, Otvos J . Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26(4):847-70. DOI: 10.1016/j.cll.2006.07.006. View

5.
Asztalos B, Schaefer E . HDL in atherosclerosis: actor or bystander?. Atheroscler Suppl. 2003; 4(1):21-9. DOI: 10.1016/s1567-5688(03)00006-0. View